$AVNS

Delgado Sigfrido sold (to issuer) $2.8M of AVNS

Delgado Sigfrido (SVP, Operations) sold (to issuer) 110,627 shares of AVANOS MEDICAL, INC. (AVNS) at $25.00 ($2.77M total) across 2 trades on 2026-07-27.

Original reporting
SEC EDGAR · Delgado Sigfrido
Published Jul 28, 2026, 9:40 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 28, 2026, 9:45 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$AVNS
Neutral
high confidence
Mentioned
$AVNS
Relevance
6/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$AVNSNeutralLow
01

Why it matters

The disclosure provides a fresh datapoint on insider activity (sale to issuer) but does not include any new guidance, deal, litigation, or operating update.

02

Market read

Traders may note insider selling, but the filing lacks fundamental catalysts, so it is unlikely to drive sustained repricing.

03

What to watch

No 10b5-1 plan is cited, but the filing also shows the insider ended with 0 shares, which can be consistent with scheduled or non-informational transactions.

Relevance 6/10Novelty 2/10Timing: after-hours, filed 2026-07-28 for a 2026-07-27 insider sale

Background

The article is an SEC Form 4 insider transaction disclosure for AVANOS MEDICAL, Inc.

Company-level read

Ticker impact

$AVNSNeutralHigh confidence
Context

AVANOS MEDICAL disclosed an insider sale to the issuer of 110,627 shares by SVP Operations Delgado Sigfrido at $25.00/share on 2026-07-27.

Expected impact

Likely minimal near-term impact; any effect is more sentiment-driven than fundamental.

Evidence & confidence

The filing is a Form 4 insider sale to the issuer with a fixed transaction price and no accompanying operational, financial, or regulatory catalyst in the text.

Market effects

No sector read-through is provided; this is company-specific insider dealing.

None indicated.

None indicated.

Counterpoint

The sale is coded as a sale to the issuer, which can reflect administrative liquidity or buyback-related mechanics rather than bearish conviction.

Key entities

  • AVANOS MEDICAL, INC.

    Subject of the Form 4 insider transaction disclosure.

  • Delgado Sigfrido

    SVP, Operations who sold shares to the issuer.

Related articles

$AVNSLow

AVANOS MEDICAL, INC. (AVNS): Completion of Acquisition or Disposition of Assets

AVANOS MEDICAL, INC. (AVNS) filed an SEC Form 8-K — Completion of Acquisition or Disposition of Assets. EX-10.1 4 avnsform8k_07272026xex101.htm EX-10.1 Document Execution Version CREDIT AGREEMENT dated as of July 27, 2026 among A-AV MERGERSUB, INC., as the Initial Borrower, AVANOS MEDICAL, INC., as the Borrower Representative, A-AV ACQUIRECO, INC., as a Borrower, A-AV INTERMEDIATEC